Company / PP&E (Net)
ResMed PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$550.8M
FY2025
5-year range
$463.5M / $550.8M
FY2021-FY2025
Trend
+0.5%
vs FY2024
Sector context
#48 of 135
Health Care
What the data says
At $551M, ResMed's pp&e (net) ranks #48 of 135 in the Health Care sector. PP&E (Net) has increased for 7 consecutive years, from $387M in FY2018 to $551M in FY2025.
Based on SEC 10-K filings.
$551M in FY2025 with a 5-year CAGR of +5.7%.
Improved from $538M to $551M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +3.4%
- 5-Year CAGR
- +5.7%
- 10-Year CAGR
- -
Sector benchmark
#48 of 135 in Health CareTop 36% of 135This company $550.8M Sector average $1.4B
▼
-59.6% below sector average
Key checks
Key Insights
- ResMed's pp&e (net) has grown for 7 consecutive years.
- 5-year CAGR of +5.7%, indicating consistent growth.
- In FY2025, pp&e (net) increased 0.5% year-over-year.
- Ranks #48 out of 135 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $550.8M | +0.5% |
| FY2024 | $548.0M | +1.9% |
| FY2023 | $537.9M | +8.0% |
| FY2022 | $498.2M | +7.5% |
| FY2021 | $463.5M | +11.1% |
| FY2020 | $417.3M | +7.7% |
| FY2019 | $387.5M | +0.2% |
| FY2018 | $386.6M | -2.0% |
| FY2017 | $394.2M | +2.6% |
| FY2016 | $384.3M | -0.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026